Skip to content

Study · Animal study (in vivo) · rat · 2019

7 results

Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.

Perovic D, Kolenc D, Bilic V, Somun N, Drmic D, Elabjer E, Buljat G, Seiwerth S, Sikiric P

Journal of orthopaedic surgery and research2 Jul 2019Cited by 25 (Europe PMC)

PMID31266512 (opens in a new tab)PMCIDPMC6604284 (opens in a new tab)DOI10.1186/s13018-019-1242-6 (opens in a new tab)PepBankPUB-31266512
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

BackgroundWe focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model. BPC 157, of which the LD1 has not been achieved, has been implemented as an anti-ulcer peptide in inflammatory bowel disease trials and recently in a multiple sclerosis trial. In animals, BPC 157 has an anti-inflammatory effect and therapeutic effects in functional recovery and the rescue of somatosensory neurons in the sciatic nerve after transection, upon brain injury after concussive trauma, and in severe encephalopathies. Additionally, BPC 157 affects various molecular pathways.MethodsTherefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury. The injury procedure involved laminectomy (level L2-L3) and a 60-s compression (neurosurgical piston (60-66 g) of the exposed dural sac of the sacrocaudal spinal cord). Assessments were performed at 1, 4, 7, 15, 30, 90, 180, and 360 days after injury.ResultsAll of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail, no autotomy, and resolved spasticity by day 15. BPC 157 application largely counteracted changes at the microscopic level, including the formation of vacuoles and the loss of axons in the white matter, the formation of edema and the loss of motoneurons in the gray matter, and a decreased number of large myelinated axons in the rat caudal nerve from day 7. EMG recordings showed a markedly lower motor unit potential in the tail muscle.ConclusionAxonal and neuronal necrosis, demyelination, and cyst formation were counteracted. The functional rescue provided by BPC 157 after spinal cord injury implies that BPC 157 therapy can impact all stages of the secondary injury phase.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, BPC‑157 gave consistent clinical improvement with increasingly better motor function of the tail.

    In plain wordsIn rats with spinal cord injury, BPC‑157 led to steadily better tail movement.

    Peptide
    BPC-157
    Outcome
    IncreaseMotor function of the tail
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    All of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail, no autotomy, and resolved spasticity by day 15.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, rats that received BPC‑157 showed no autotomy.

    In plain wordsIn rats with spinal cord injury, those given BPC‑157 did not show self-injury of the tail.

    Peptide
    BPC-157
    Outcome
    DecreaseAutotomy
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    All of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail, no autotomy, and resolved spasticity by day 15.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, spasticity resolved by day 15 in rats that received BPC‑157.

    In plain wordsIn rats with spinal cord injury, muscle stiffness went away by day 15 after BPC‑157.

    Peptide
    BPC-157
    Outcome
    DecreaseSpasticity
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    All of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail, no autotomy, and resolved spasticity by day 15.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, BPC‑157 largely counteracted vacuole formation and axon loss in the white matter.

    In plain wordsIn rats with spinal cord injury, BPC‑157 largely reduced damage to nerve fibres in the white matter.

    Peptide
    BPC-157
    Outcome
    DecreaseWhite matter vacuoles and axon loss
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 application largely counteracted changes at the microscopic level, including the formation of vacuoles and the loss of axons in the white matter, the formation of edema and the loss of motoneurons in the gray matter, and a decreased number of large myelinated axons in the rat caudal nerve from day 7.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, BPC‑157 largely counteracted edema and loss of motoneurons in the gray matter.

    In plain wordsIn rats with spinal cord injury, BPC‑157 largely reduced swelling and loss of motor nerve cells in the gray matter.

    Peptide
    BPC-157
    Outcome
    DecreaseGray matter edema and motoneuron loss
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 application largely counteracted changes at the microscopic level, including the formation of vacuoles and the loss of axons in the white matter, the formation of edema and the loss of motoneurons in the gray matter, and a decreased number of large myelinated axons in the rat caudal nerve from day 7.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, BPC‑157 largely counteracted the decrease in the number of large myelinated axons in the caudal nerve from day 7.

    In plain wordsIn rats with spinal cord injury, BPC‑157 largely prevented the loss of large insulated nerve fibres in the tail nerve.

    Peptide
    BPC-157
    Outcome
    IncreaseLarge myelinated axons in the caudal nerve
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 application largely counteracted changes at the microscopic level, including the formation of vacuoles and the loss of axons in the white matter, the formation of edema and the loss of motoneurons in the gray matter, and a decreased number of large myelinated axons in the rat caudal nerve from day 7.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with spinal cord injury, BPC‑157 counteracted axonal and neuronal necrosis, demyelination and cyst formation.

    In plain wordsIn rats with spinal cord injury, BPC‑157 counteracted nerve cell death, loss of nerve insulation and cyst formation.

    Peptide
    BPC-157
    Outcome
    DecreaseAxonal and neuronal necrosis, demyelination, cyst formation
    Study

    ratn: not reported in source

    Rat spinal cord injury by 60-s compression at L2-L3
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    200 or 2 µg/kg · intraperitoneal · one-timeAs given in this study (rat).

    Source sentences

    Summary
    Axonal and neuronal necrosis, demyelination, and cyst formation were counteracted.
    2 context sentences
    Summary · context
    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model.
    Summary · context
    Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 μg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.